Join Growin Stock Community!

Alpha cognition inc. common stockACOG.US Overview

US StockHealthcare
(No presentation for ACOG)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ACOG AI Insights

ACOG Overall Performance

ACOG AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ACOG Recent Performance

-

Alpha cognition inc. common stock

0.05%

Avg of Sector

-0.31%

S&P500

ACOG PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ACOG Key Information

ACOG Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ACOG Profile

Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

Price of ACOG

ACOG FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ACOG Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.31
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
17.56
PB Ratio
3.85
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
73.09%
Net Margin
-262.18%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.31
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
17.56
PB Ratio
3.85
Price-to-FCF
-
Gross Margin
73.09%
Net Margin
-262.18%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ACOG's latest earnings report released?

    The most recent financial report for Alpha cognition inc. common stock (ACOG) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ACOG's short-term business performance and financial health. For the latest updates on ACOG's earnings releases, visit this page regularly.

  • What is the operating profit of ACOG?

    According to the latest financial report, Alpha cognition inc. common stock (ACOG) reported an Operating Profit of -5.31M with an Operating Margin of -186.99% this period, representing a decline of 113.52% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ACOG's revenue growth?

    In the latest financial report, Alpha cognition inc. common stock (ACOG) announced revenue of 2.84M, with a Year-Over-Year growth rate of 0%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does ACOG have?

    At the end of the period, Alpha cognition inc. common stock (ACOG) held Total Cash and Cash Equivalents of 35.46M, accounting for 0.77 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ACOG go with three margins increasing?

    In the latest report, Alpha cognition inc. common stock (ACOG) did not achieve the “three margins increasing” benchmark, with a gross margin of 77.9%%, operating margin of -186.99%%, and net margin of -46.4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ACOG's profit trajectory and future growth potential.

  • Is ACOG's EPS continuing to grow?

    According to the past four quarterly reports, Alpha cognition inc. common stock (ACOG)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.08. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ACOG?

    Alpha cognition inc. common stock (ACOG)'s Free Cash Flow (FCF) for the period is -5.36M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 239.93% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.